Genetic Variants in RORA and DNMT1 Associated with Cutaneous Melanoma Survival

Overview

Journal Int J Cancer

Specialty Oncology

Date 2018 Jan 10

PMID 29313974

Citations 9

Authors

Bo Li

Yanru Wang

Yinghui Xu

Hongliang Liu

Wendy Bloomer

Dakai Zhu

Christopher I Amos

Shenying Fang

Jeffrey E Lee

Xin Li

Jiali Han

Qingyi Wei

Affiliations

Soon will be listed here.

Abstract

Cutaneous melanoma (CM) is considered as a steroid hormone-related malignancy. However, few studies have evaluated the roles of genetic variants encoding steroid hormone receptor genes and their related regulators (SHR-related genes) in CM-specific survival (CMSS). Here, we performed a pathway-based analysis to evaluate genetic variants of 191 SHR-related genes in 858 CMSS patients using a dataset from a genome-wide association study (GWAS) from The University of Texas MD Anderson Cancer Center (MDACC), and then validated the results in an additional dataset of 409 patients from the Harvard GWAS. Using multivariate Cox proportional hazards regression analysis, we identified three-independent SNPs (RORA rs782917 G > A, RORA rs17204952 C > T and DNMT1 rs7253062 G > A) as predictors of CMSS, with a variant-allele attributed hazards ratio (HR) and 95% confidence interval of 1.62 (1.25-2.09), 1.60 (1.20-2.13) and 1.52 (1.20-1.94), respectively. Combined analysis of risk genotypes of these three SNPs revealed a decreased CMSS in a dose-response manner as the number of risk genotypes increased (p < 0.001); however, no improvement in the prediction model was observed (area under the curve [AUC] = 79.6-80.8%, p = 0.656), when these risk genotypes were added to the model containing clinical variables. Our findings suggest that genetic variants of RORA and DNMT1 may be promising biomarkers for CMSS, but these results needed to be validated in future larger studies.

Citing Articles

The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies.

Wang J, Shao F, Yu Q, Ye L, Wusiman D, Wu R Research (Wash D C). 2025; 8:0612.

PMID: 40046513 PMC: 11880593. DOI: 10.34133/research.0612.

Exploring new mechanisms in cancer molecular pathways and pathogenic cell transformation: PIP4K2A as a prognostic marker and therapeutic target in cutaneous malignant melanoma.

Luo W, Song D, Shen T, He Y, Du H, Si M Discov Oncol. 2024; 15(1):697.

PMID: 39579298 PMC: 11585527. DOI: 10.1007/s12672-024-01555-3.

Identifying novel circadian rhythm biomarkers for diagnosis and prognosis of melanoma by an integrated bioinformatics and machine learning approach.

Xu Y, Zeng C, Bin J, Tang H, Li W Aging (Albany NY). 2024; 16(16):11824-11842.

PMID: 39213172 PMC: 11386929. DOI: 10.18632/aging.205961.

Oncogenic DNA methyltransferase 1 activates the PI3K/AKT/mTOR signalling by blocking the binding of HSPB8 and BAG3 in melanoma.

Yang Y, Ma S, Ye Z, Zheng Y, Zheng Z, Liu X Epigenetics. 2023; 18(1):2239607.

PMID: 37523636 PMC: 10392740. DOI: 10.1080/15592294.2023.2239607.

Single nucleotide polymorphisms in and of the lymphocyte activation-related pathway affect survival of lung cancer patients.

Du H, Mu R, Liu L, Liu H, Luo S, Patz Jr E Transl Lung Cancer Res. 2022; 11(5):890-901.

PMID: 35693292 PMC: 9186164. DOI: 10.21037/tlcr-22-104.

References

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Mitkov M, Joseph R, Copland 3rd J . Steroid hormone influence on melanomagenesis. Mol Cell Endocrinol. 2015; 417:94-102. DOI: 10.1016/j.mce.2015.09.020. View

Zhu Y, McAvoy S, Kuhn R, Smith D . RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene. 2006; 25(20):2901-8. DOI: 10.1038/sj.onc.1209314. View

Venza M, Visalli M, Catalano T, Biondo C, Beninati C, Teti D . DNA methylation-induced E-cadherin silencing is correlated with the clinicopathological features of melanoma. Oncol Rep. 2016; 35(4):2451-60. DOI: 10.3892/or.2016.4618. View

Zhu H, Dong D, Li F, Liu D, Wang L, Fu J . Clinicopathologic features and prognostic factors in patients with non-cutaneous malignant melanoma: a single-center retrospective study of 71 cases. Int J Dermatol. 2015; 54(12):1390-5. DOI: 10.1111/ijd.12745. View

Tryka K, Hao L, Sturcke A, Jin Y, Wang Z, Ziyabari L . NCBI's Database of Genotypes and Phenotypes: dbGaP. Nucleic Acids Res. 2013; 42(Database issue):D975-9. PMC: 3965052. DOI: 10.1093/nar/gkt1211. View

Marzagalli M, Montagnani Marelli M, Casati L, Fontana F, Moretti R, Limonta P . Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility. Front Endocrinol (Lausanne). 2016; 7:140. PMC: 5080294. DOI: 10.3389/fendo.2016.00140. View

Lappalainen T, Sammeth M, Friedlander M, t Hoen P, Monlong J, Rivas M . Transcriptome and genome sequencing uncovers functional variation in humans. Nature. 2013; 501(7468):506-11. PMC: 3918453. DOI: 10.1038/nature12531. View

Ramaraj P, Cox J . In vitro effect of progesterone on human melanoma (BLM) cell growth. Int J Clin Exp Med. 2015; 7(11):3941-53. PMC: 4276160. View

10.

Bannister-Tyrrell M, Roberts C, Hasovits C, Nippita T, Ford J . Incidence and outcomes of pregnancy-associated melanoma in New South Wales 1994-2008. Aust N Z J Obstet Gynaecol. 2014; 55(2):116-22. DOI: 10.1111/ajo.12279. View

11.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

12.

Mailman M, Feolo M, Jin Y, Kimura M, Tryka K, Bagoutdinov R . The NCBI dbGaP database of genotypes and phenotypes. Nat Genet. 2007; 39(10):1181-6. PMC: 2031016. DOI: 10.1038/ng1007-1181. View

13.

Amos C, Wang L, Lee J, Gershenwald J, Chen W, Fang S . Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet. 2011; 20(24):5012-23. PMC: 3298855. DOI: 10.1093/hmg/ddr415. View

14.

Marzagalli M, Casati L, Moretti R, Montagnani Marelli M, Limonta P . Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines. PLoS One. 2015; 10(7):e0134396. PMC: 4520550. DOI: 10.1371/journal.pone.0134396. View

15.

Benna C, Helfrich-Forster C, Rajendran S, Monticelli H, Pilati P, Nitti D . Genetic variation of clock genes and cancer risk: a field synopsis and meta-analysis. Oncotarget. 2017; 8(14):23978-23995. PMC: 5410358. DOI: 10.18632/oncotarget.15074. View

16.

Biernacka J, Tang R, Li J, McDonnell S, Rabe K, Sinnwell J . Assessment of genotype imputation methods. BMC Proc. 2009; 3 Suppl 7:S5. PMC: 2795949. DOI: 10.1186/1753-6561-3-s7-s5. View

17.

Allil P, Visconti M, Castrucci A, Isoldi M . Photoperiod and testosterone modulate growth and melanogenesis of s91 murine melanoma. Med Chem. 2008; 4(2):100-5. DOI: 10.2174/157340608783789185. View

18.

Molognoni F, Machado de Melo F, Da Silva C, Jasiulionis M . Ras and Rac1, frequently mutated in melanomas, are activated by superoxide anion, modulate Dnmt1 level and are causally related to melanocyte malignant transformation. PLoS One. 2013; 8(12):e81937. PMC: 3864863. DOI: 10.1371/journal.pone.0081937. View

19.

de Giorgi V, Gori A, Gandini S, Papi F, Grazzini M, Rossari S . Oestrogen receptor beta and melanoma: a comparative study. Br J Dermatol. 2012; 168(3):513-9. DOI: 10.1111/bjd.12056. View

20.

Chambless L, Diao G . Estimation of time-dependent area under the ROC curve for long-term risk prediction. Stat Med. 2005; 25(20):3474-86. DOI: 10.1002/sim.2299. View